Afatinib Versus Methotrexate (Mtx) As Second-Line Treatment for Patients with Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (Hnscc) Who Progressed After Platinum-Based Therapy: Primary Efficacy Results of Lux-Head & Neck 1, a Phase III Trial
J-P. Machiels(Cliniques Universitaires Saint-Luc), Ezra E.W. Cohen(Moores Cancer Center), Jan B. Vermorken(University of Antwerp), J. Guigay(Centre Antoine Lacassagne), Makoto Tahara(National Cancer Center Hospital East), L. Svensson(Boehringer Ingelheim (Denmark)), Jérôme Fayette(Université Claude Bernard Lyon 1), Thomas Gauler, Lisa Licitra(University of Milan), Luciano de Souza Viana(Hospital de Câncer de Barretos), Ulrich Keilholz(German Cancer Research Center), Robert I. Haddad(Georgetown University), Gilberto de Castro(Instituto do Câncer do Estado de São Paulo), Didier Cupissol(Institut de Recherche en Cancérologie de Montpellier), E. Ehrnrooth(Boehringer Ingelheim (Germany)), J.M. del Campo(Vall d'Hebron Hospital Universitari), Francesco Caponigro, Paul M. Clément(Universitair Ziekenhuis Leuven), Juan J. Grau(Hospital Clínic de Barcelona), Xiuyu Julie Cong(Boehringer Ingelheim (United States))
Cited by 11
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k